ALT5 Sigma (NASDAQ:ALTS) Shares Down 2.2% – What’s Next?

ALT5 Sigma Corporation (NASDAQ:ALTS)’s stock price was down 2.2% during mid-day trading on Thursday . The stock traded as low as $1.29 and last traded at $1.32. Approximately 1,152,010 shares changed hands during trading, a decline of 43% from the average daily volume of 2,021,641 shares. The stock had previously closed at $1.35.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ALT5 Sigma in a report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, ALT5 Sigma has a consensus rating of “Sell”.

ALT5 Sigma Trading Down 2.2%

The company has a current ratio of 0.79, a quick ratio of 0.79 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average price of $1.66 and a two-hundred day moving average price of $2.01.

ALT5 Sigma (NASDAQ:ALTS) last released its quarterly earnings data on Monday, January 12th. The company reported $0.29 EPS for the quarter. The company had revenue of $7.58 million during the quarter. ALT5 Sigma had a net margin of 133.06% and a return on equity of 8.60%.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in ALTS. Geode Capital Management LLC raised its stake in ALT5 Sigma by 27.6% in the second quarter. Geode Capital Management LLC now owns 194,813 shares of the company’s stock valued at $1,412,000 after purchasing an additional 42,157 shares in the last quarter. Jane Street Group LLC purchased a new stake in ALT5 Sigma during the second quarter valued at about $380,000. Bridgeway Capital Management LLC lifted its stake in ALT5 Sigma by 9.4% during the second quarter. Bridgeway Capital Management LLC now owns 19,339 shares of the company’s stock worth $140,000 after purchasing an additional 1,661 shares during the last quarter. Arkadios Wealth Advisors bought a new stake in ALT5 Sigma during the third quarter worth about $62,000. Finally, First Citizens Bank & Trust Co. purchased a new position in shares of ALT5 Sigma in the 3rd quarter worth about $35,000. 6.27% of the stock is currently owned by hedge funds and other institutional investors.

ALT5 Sigma Company Profile

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties.